Clinitech Laboratory Ltd
Fundamental Score
Clinitech Laboratory Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of CTLLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (15.92%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 21.07 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (36.36%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (24.51%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (10.14x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (62.42%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
6 factors identified
Below-Average Return on Equity (5.49%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.15%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Negative Free Cash Flow (₹-3.61 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 0.32%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Clinitech Laboratory Ltd
About CTLLAB
Business Overview
Clinitech Laboratory Limited engages in the healthcare business in India. The company provides services including pathology testing laboratories, diagnostic centers, scan centers, X-ray and ECG clinics, and other services. The company was founded in 1990 and is headquartered in Navi Mumbai, India.
Company Details
Key Leadership
CTLLAB Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Clinitech Laboratory Ltd (CTLLAB)?
As of 29 Jan 2026, 10:32 am IST, Clinitech Laboratory Ltd (CTLLAB) is currently trading at ₹34.89. The stock has a market capitalization of ₹9.90 (Cr).
Is CTLLAB share price Overvalued or Undervalued?
CTLLAB is currently trading at a P/E ratio of 21.07x, compared to the industry average of 39.28x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Clinitech Laboratory Ltd share price?
Key factors influencing CTLLAB's price include its quarterly earnings growth (Sales Growth: 24.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Clinitech Laboratory Ltd a good stock for long-term investment?
Clinitech Laboratory Ltd shows a 5-year Profit Growth of N/A% and an ROE of 5.49%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing.
How does Clinitech Laboratory Ltd compare with its industry peers?
Clinitech Laboratory Ltd competes with major peers in the Healthcare Service Provider. Investors should compare CTLLAB's P/E of 21.07x and ROE of 5.49% against the industry averages to determine its competitive standing.
What is the P/E ratio of CTLLAB and what does it mean?
CTLLAB has a P/E ratio of 21.07x compared to the industry average of 39.28x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings.
How is CTLLAB performing according to Bull Run's analysis?
CTLLAB has a Bull Run fundamental score of 45.2/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does CTLLAB belong to?
CTLLAB operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Clinitech Laboratory Ltd.
What is Return on Equity (ROE) and why is it important for CTLLAB?
CTLLAB has an ROE of 5.49%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Clinitech Laboratory Ltd generates profits from shareholders' equity.
How is CTLLAB's debt-to-equity ratio and what does it indicate?
CTLLAB has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is CTLLAB's dividend yield and is it a good dividend stock?
CTLLAB offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has CTLLAB grown over the past 5 years?
CTLLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in CTLLAB and why does it matter?
Promoters hold 62.42% of CTLLAB shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is CTLLAB's market capitalization category?
CTLLAB has a market capitalization of ₹10 crores, placing it in the Small-cap category.
How volatile is CTLLAB stock?
CTLLAB has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for CTLLAB?
CTLLAB has a 52-week high of ₹N/A and low of ₹N/A.
What is CTLLAB's operating profit margin trend?
CTLLAB has a 5-year average Operating Profit Margin (OPM) of 15.92%, indicating the company's operational efficiency.
How is CTLLAB's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 24.51% and YoY Profit Growth of 36.36%.
What is the institutional holding pattern in CTLLAB?
CTLLAB has FII holding of 0.32% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.